Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endotracheal N-acetylcysteine and heparin for acute respiratory distress syndrome and lung contusion
IRCT20190205042631N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-blind trial of acetylcysteine and heparin in acute respiratory distress syndrome (ARDS) and Lung Contusion (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoint: Improvement of respiratory signs. Started Feb 2019; status: completed.
02
Drugs
acetylcysteineheparin
03
Conditions
acute respiratory distress syndrome (ARDS)Lung Contusion
Beyond the preview
Go deeper on IRCT20190205042631N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190205042631N1.